• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: April 30, 2025

Key Takeaways

  • JAK inhibitors for atopic dermatitis show similar safety profiles to IL-4/-13 inhibitors, with no increased cardiovascular or cancer risks.
  • Bempikibart has received FDA Fast Track Designation, offering hope for severe alopecia areata treatment amid unmet needs.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Journal Digest: April 30

This review of the latest dermatologic studies includes insights into the environmental impact of dermatology, submicrobial dosing of antibiotics in dermatology, and more.

Top 5 Articles of the Month: April

Explore the top headlines of the week including insights on recalls, expert pearls, and more.

Dermatology Times April 2025 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of April.

Celebrating Rosacea Awareness Month 2025 with Dermatology Times

Explore the latest insights, strategies, and treatments for patients with rosacea as Dermatology Times looks back on Rosacea Awareness Month.

JAKi and IL-4/-13i Show Similar Safety Profiles in AD

New research reveals JAK inhibitors for atopic dermatitis do not increase cardiovascular or cancer risks compared to IL-4/-13 inhibitors, offering reassurance for patients.

Q32 Bio’s Bempikibart Receives FDA Fast Track Designation for Alopecia Areata

The development of bempikibart offers hope for effective treatment of severe alopecia areata amid unmet medical needs.

Optimizing Atopic Dermatitis Care With Emerging Topical Therapeutics

In a recent Dermatology Times Case-Based Roundtable event, Lisa Swanson, MD, discussed 3 diverse atopic dermatitis patient cases.

Expanding Topical Non-Steroidal Options in Atopic Dermatitis to Reduce Chronic Steroid Use

Raj Chovatiya, MD, PhD, MSCI, reviews the limitations of chronic steroid use and highlights available topicals, including ruxolitinib, roflumilast, and tapinarof.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.